The US FDA Approves Innovate’s MediBeacon Transdermal GFR System to Evaluate Renal Function

Shots: The US FDA has approved MediBeacon TGFR to assess patients with normal or impaired renal function The system met FDA-approved 1EP of 94% P30 value (% of GFR estimates within ±30% of mGFR) in patients with varied GFR & skin tones. The approval aligns with recent data publication in support of Lumitrace in…